Introduction
Methods
Recruitment and Procedure
Assessment
Treatment Allocation
Participants
Intervention
Self-Help Videos
Self-Help Website
Assessment
Primary Outcome
Secondary Outcomes
Strategy of Data Analysis
Results
Baseline Characteristics
Website (n = 74) | Videos (n = 73) | WLC (n = 70) | Statistics | |
---|---|---|---|---|
Demographic characteristics | ||||
Age in years | 31.73 (8.10) | 32.62 (9.16) | 33.19 (9.56) | F(2,214) = 0.49, p = .616, ηp2 = 0.005 |
Gender (female/male) | 66/8 | 71/2 | 62/8 | χ2 (2) = 4.48, p = .106 |
Prior psychotherapeutic treatment | 13.6% | 15.1% | 11.45 | χ2 (2) = 0.41, p = .814 |
Medication | ||||
Antidepressants | 12.2% | 15.1% | 10.0% | χ2 (2) = 0.85, p = .654 |
Other psychotropic substances | 1.4% | 0.0% | 1.4% | χ2 (2) = 1.03, p = .599 |
Point prevalence of BFRBs | ||||
Dermatillomania | 78.4% | 79.5% | 77.1% | χ2 (2) = 0.11, p = .945 |
Onychophagia | 47.3% | 35.6% | 41.4% | χ2 (2) = 2.07, p = .356 |
Trichotillomania | 16.2% | 12.3% | 12.9% | χ2 (2) = 0.55, p = .761 |
Cavitadaxia | 17.6% | 28.8% | 22.9% | χ2 (2) = 2.60, p = .272 |
Other | 9.5% | 9.6% | 11.4% | χ2 (2) = 0.19, p = .910 |
Lifetime prevalence of psychiatric disorders | ||||
No psychiatric diagnosis | 55.4% | 50.7% | 55.7% | χ2 (2) = 0.46, p = .793 |
Depression | 25.7% | 31.5% | 25.7% | χ2 (2) = 0.82, p = .664 |
Obsessive compulsive disorder | 2.7% | 1.4% | 7.1% | χ2 (2) = 3.66, p = .160 |
Anxiety disorder | 6.8% | 16.4% | 10.0% | χ2 (2) = 3.62, p = .164 |
Post-traumatic stress disorder | 12.2% | 8.2% | 10.0% | χ2 (2) = 0.63, p = .730 |
Anorexia nervosa | 2.7% | 2.7% | 2.9% | χ2 (2) < 0.01, p = .998 |
Bulimia nervosa | 5.4% | 1.4% | 4.3% | χ2 (2) = 1.80, p = .409 |
Substance or alcohol abuse | 0.0% | 1.4% | 0.0% | χ2 (2) = 1.98, p = .371 |
Attention deficit hyperactivity disorder | 4.1% | 1.4% | 1.4% | χ2 (2) = 1.53, p = .466 |
Generic Body-Focused Repetitive Behavior Scale 45 (GBS-45) | ||||
GBS-45 total score | 21.51 (9.87) | 21.94 (10.77) | 21.73 (12.68) | F (2214) = 0.03, p = .974, ηp2 < 0.001 |
GBS-45 severity | 13.96 (6.57) | 14.23 (7.03) | 13.73 (7.52) | F (2214) = 0.09, p = .496, ηp2 = 0.007 |
GBS-45 impairment | 7.55 (4.05) | 7.71 (4.98) | 8.00 (6.25) | F (2214) = 0.24, p = .914, ηp2 = 0.001 |
Quality of life (WHOQOL-BREF Global Item) | ||||
WHOQOL-BREF global item | 3.57 (0.83) | 3.41 (0.91) | 3.54 (0.83) | F (2214) = 0.70, p = .496, ηp2 = 0.007 |
Depressive symptoms (PHQ-9) | ||||
PHQ-9 | 7.34 (4.61) | 9.05 (5.63) | 8.34 (5.39) | F (2214) = 2.01, p = .137, ηp2 = 0.018 |
Adherence and Efficacy
Intention-to-treat (ITT) (W: n = 74; V: n = 73; WLC: n = 70) | Complete Cases (CC) (W: n = 51; V: n = 55; WLC: n = 49) | Per-Protocol (PP) (W: n = 42; V: n = 41; WLC: n = 49) | |
---|---|---|---|
T = Time; I = Interaction; [Differences between W, V, and WLC in square brackets] | |||
GBS-45 total score | T: F(1,214) = 14.02, p < .001, ηp2 = 0.061 I: F(2,214) = 0.26, p = .770, ηp2 = 0.002 [V = W: p = .471; V = WLC: p = .689; WLC = W: p = .755] | T: F(1,152) = 10.75, p = .001, ηp2 = 0.066 I: F(2,152) = 0.72, p = .491, ηp2 = 0.009 [V = W: p = .679; V = WLC: p = .238; W = WLC: p = .449] | T: F(1,129) = 11.78, p < .001, ηp2 = 0.084 I: F(2,129) = 1.09, p = .338, ηp2 = 0.017 [V = W: p = .658; V = WLC: p = .329; W = WLC: p = .658] |
GBS-45 severity | T: F(1,214) = 28.04, p < .001, ηp2 = 0.116 I: F(2,214) = 0.65, p = .524, ηp2 = 0.006 [V = W: p = .639; V = WLC: p = .112; W = WLC: p = .276] | T: F(1,152) = 18.64, p < .001, ηp2 = 0.109 I: F(2,152) = 1.02, p = .362, ηp2 = 0.013 [W = V: p = .971; V = WLC: p = .217; W = WLC: p = .212] | T: F(1,129) = 18.91, p < .001, ηp2 = 0.128 I: F(2,129) = 1.47, p = .233, ηp2 = 0.022 [V = W: p = .995; V = WLC: p = .145; W = WLC: p = .146] |
GBS severity Dermatillomania | T: F(1,167) = 51.49, p < .001, ηp2 = 0.236 I: F(2,167) = 0.15, p = .858, ηp2 = 0.002 [W = V: p = .611; WLC = V: p = .951; W = WLC: p = .661] | T: F(1,113) = 29.34, p < .001, ηp2 = 0.206 I: F(2,113) = 1.17, p = .314, ηp2 = 0.020 [W = V: p = .365; V = WLC: p = .501; W = WLC: p = .131] | T: F(1,100) = 30.33, p < .001, ηp2 = 0.233 I: F(2,100) = 1.22, p = .300, ηp2 = 0.024 [W = V: p = .745; V = WLC: p = .246; W = WLC: p = .143] |
GBS severity Onychophagia | T: F(1,87) = 26.14, p < .001, ηp2 = 0.231 I: F(2,87) = 6.76, p = .002, ηp2 = 0.135 [V > W: p = .008; V > WLC: p < .001; W = WLC: p = .313] | T: F(1,51) = 9.83, p = .003, ηp2 = 0.162 I: F(2,51) = 8.38, p < .001, ηp2 = 0.247 [V > W: p = .036; V > WLC: p < 001; W > WLC: p = .034] | T: F(1,45) = 36.20, p = .002, ηp2 = 0.198 I: F(2,45) = 26.68, p < .001, ηp2 = 0.267 [V ≥ W: p = .098; V > WLC: p < .001; W > WLC: p = .010] |
GBS severity Trichotillomania | T: F(1,27) = 0.91, p = .350, ηp2 = 0.032 I: F(2,27) = 64.15, p = .027, ηp2 = 0.235 [V ≥ W: p = .054; WLC = V: p = .511; WLC > W: p = .011] | T: F(1,17) = 1.40, p = .252, ηp2 = 0.076 I: F(2,17) = 1.64, p = .224, ηp2 = 0.161 [V = W: p = .435; WLC = V: p = .274; WLC ≥ W: p = .088] | T: F(1,11) = 0.43, p = .528, ηp2 = 0.037 I: F(2,11) = 1.13, p = .357, ηp2 = 0.171 [V = W: p = .618; WLC = V: p = .392; WLC = W: p = .164] |
GBS severity Cavitadaxia | T: F(1,39) = 0.23, p = .634, ηp2 = 0.006 I: F(2,39) = 1.81, p = .176, ηp2 = 0.085 [W = V: p = .496; WLC = V: p = .384; WLC ≥ W: p = .092] | T: F(1,27) = 1.77, p = .194, ηp2 = 0.062 I: F(2,27) = 0.12, p = .889, ηp2 = 0.009 [V = W: p = .640; V = WLC: p = .946; WLC = W: p = .680] | T: F(1,23) = 1.94, p = .178, ηp2 = 0.078 I: F(2,23) = 0.20, p = .817, ηp2 = 0.017 [V = W: p = .530; V = WLC: p = .742; WLC = W: p = .699] |
GBS severity other BFRBs | T: F(1,17) = 6.64, p = .020, ηp2 = 0.281 I: F(2,17) = 1.88, p = .182, ηp2 = 0.181 [V = W: p = .463; WLC = V: p = .396; WLC = W: p = .117] | T: F(1,4) = 0.47, p = .532, ηp2 = 0.104 I: F(2,4) = 2.11, p = .237, ηp2 = 0.513 [V = W: p = .303; V = WLC: p = .110; W = WLC: p = .492] | T: F(1,4) = 0.47, p = .532, ηp2 = 0.104 I: F(2,4) = 2.11, p = .237, ηp2 = 0.513 [V = W: p = .303; V = WLC: p = .110; W = WLC: p = .492] |
GBS impairment | T: F(1,212) = 0.32, p = .570, ηp2 = 0.002 I: F(2,212) = 1.27, p = .284, ηp2 = 0.012 [W = V: p = .336; V = WLC: p = .384; W ≥ WLC: p = .069] | T: F(1,152) = 1.75, p = .189, ηp2 = 0.011 I: F(2,152) = 0.59, p = .558, ηp2 = 0.008 [V = W: p = .343; V = WLC: p = .366; WLC = W: p = .974] | T: F(1,129) = 2.51, p = .115, ηp2 = 0.019 I: F(2,129) = 0.75, p = .475, ηp2 = 0.011 [V = W: p = .335; V = WLC: p = .254; W = WLC: p = .886] |
GBS impairment Dermatillomania | T: F(1,167) = 2.23, p < .001, ηp2 = 0.113 I: F(2,167) = 0.48, p = .618, ηp2 = 0.006 [V = W: p = .383; V = WLC: p = .414; WLC = W: p = .968] | T: F(1,113) = 11.15, p = .001, ηp2 = 0.090 I: F(2,113) = 1.03, p = .360, ηp2 = 0.018 [V = W: p = .536; V = WLC: p = .154; W = WLC: p = .422] | T: F(1,100) = 8.98, p = .003, ηp2 = 0.082 I: F(2,100) = 0.75, p = .474, ηp2 = 0.015 [V = W: p = .671; V = WLC: p = .229; W = WLC: p = .445] |
GBS impairment Onychophagia | T: F(1,84) = 13.03, p < .001, ηp2 = 0.134 I: F(2,84) = 6.08, p = .003, ηp2 = 0.126 [V > W: p = .001; V > WLC: p = .006; WLC = W: p = .636] | T: F(1,51) = 3.31, p = .075, ηp2 = 0.061 I: F(2,51) = 3.26, p = .047, ηp2 = 0.113 [V > W: p = .026; V > WLC: p = .037; WLC = W: p = 1.000] | T: F(1,45) = 4.99, p = .031, ηp2 = 0.100 I: F(2,45) = 3.30, p = .046, ηp2 = 0.128 [V > W: p = .043; V > WLC: p = .022; WLC = W: p = .741] |
GBS impairment Trichotillomania | T: F(1,27) = 5.36, p = .028, ηp2 = 0.166 I: F(2,27) = 1.65, p = .211, ηp2 = 0.109 [V ≥ W: p = .095; V = WLC: p = .646; WLC = W: p = .228] | T: F(1,17) = 0.91, p = .353, ηp2 = 0.051 I: F(2,17) = 1.71, p = .211, ηp2 = 0.167 [V = W: p = .199; WLC = V: p = .563; WLC ≥ W: p = .097] | T: F(1,11) = 0.22, p = .648, ηp2 = 0.020 I: F(2,11) = 1.45, p = .277, ηp2 = 0.208 [V = W: p = .194; WLC = V: p = .960; WLC = W: p = .156] |
GBS impairment Cavitadaxia | T: F(1,39) = 7.02, p = .012, ηp2 = 0.153 I: F(2,39) = 1.56, p = .223, ηp2 = 0.074 [W = V: p = .236; WLC = V: p = .098; WLC = W: p = .717] | T: F(1,27) = 0.07, p = .787, ηp2 = 0.003 I: F(2,27) = 0.08, p = .922, ηp2 = 0.006 [W = V: p = .691; WLC = V: p = .867; W = WLC: p = .789] | T: F(1,23) = 0.03, p = .856, ηp2 = 0.001 I: F(2,23) = 0.05, p = .956, ηp2 = 0.004 [W = V: p = .777; V = WLC: p = .955; W = WLC: p = .802] |
GBS impairment other BFRBs | T: F(1,11) = 0.86, p = .375, ηp2 = 0.072 I: F(2,11) = 1.73, p = .223, ηp2 = 0.239 [W = V: p = .356; V > WLC: p = .043; W > WLC: p = .005] | T: F(1,4) = 0.13, p = .914, ηp2 = 0.003 I: F(2,4) = 1.11, p = .415, ηp2 = 0.356 [V = W: p = .901; V = WLC: p = .260; W = WLC: p = .308] | T: F(1,4) = 0.01, p = .914, ηp2 = 0.003 I: F(2,4) = 1.11, p = .415, ηp2 = 0.356 [V = W: p = .901; V = WLC: p = .260; W = WLC: p = .308] |
Quality of life (WHOQOL-BREF) | T: F(1,214) = 2.24, p = .136, ηp2 = 0.010 I: F(2,214) = 0.18, p = .835, ηp2 = 0.002 | T: F(1,151) = 0.81, p = .370, ηp2 = 0.005 I: F(2,151) = 0.04, p = .958, ηp2 = 0.001 | T: F(1,128) = 1.23, p = .269, ηp2 = 0.010 I: F(2,128) = 0.10, p = .906, ηp2 = 0.002 |
Depressive symptoms (PHQ-9) | T: F(1,214) = 2.05, p = .154, ηp2 = 0.009 I: F(2,214) = 0.42, p = .660, ηp2 = 0.004 | T: F(1,152) = 0.41, p = .525, ηp2 = 0.003 I: F(2,152) = 0.18, p = .834, ηp2 = 0.002 | T: F(1,129) = 1.95, p = .165, ηp2 = 0.015 I: F(2,129) = 0.01, p = .992, ηp2 < 0.001 |